Interní Med. 2007; 9(7): 343-344

Conundrums in immunotherapy of sepsis

MUDr. Roman Zazula Ph.D1, MUDr. Miroslav Průcha Ph.D2
1 Anesteziologicko-resuscitační oddělení, Fakultní Thomayerova nemocnice Praha
2 Oddělení klinické biochemie, hematologie a imunologie, Nemocnice Na Homolce, Praha

Sepsis is a clinical syndrome that results from a systemic host response to an infection. The outcome of sepsis is poor, and mortality rates are high. Sepsis is associated with the activation of multiple inflammatory pathways, including the cytokine network and the coagulation system. Sepsis can also result in an immunodepressed state that could leave patiens more susceptable to secondary nosocomial infections. Modulations of the host response to infection has been studied as an adjunctive therapeutic approach in many preclinical investigations and clinical trials. As a result of these studies our knowledge of the pathogenesis of sepsis has increased considerably.

Keywords: sepsis, septic shock, sepsis trials, immunomodulation, cytokines

Published: December 18, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Zazula R, Průcha M. Conundrums in immunotherapy of sepsis. Interní Med. 2007;9(7):343-344.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Alejandria MM, Lansang MA, Dans LF, et al. Intravenous immunoglobulins for treating sepsis and septic shock. Cochrane Database Syst Rev 2001; 2: CD001090. Go to original source...
    2. Annane D, Sebille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002; 288: 862-871. Go to original source... Go to PubMed...
    3. Bellomo R, Tetta C, Ronco C. Coupled plasma filtration adsorption. Intensive care Med., 2003; 8: 1222-1228. Go to original source... Go to PubMed...
    4. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Eng J Med 2001; 344: 699-709. Go to original source... Go to PubMed...
    5. Busund R, Koukline V, Utrobin U, et al. Plasmapheresis in severe sepsis and septic shock: prospective, randomised, controlled trial. Intensive Care Med 2002; 10: 1434-1439. Go to original source... Go to PubMed...
    6. Eichhacker PQ, Parent CH, Kalil A, et al. Risk and the efficacy of antiinflamatory agents. Retrospective and confirmatory studies of sepsis. Am J Respir Crit Care Med 2002; 166: 1197-1205. Go to original source... Go to PubMed...
    7. Kaul R, McGeer A, Norrby-Teglund A, et al. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome - a comparative observational study. Clin Infecr Dis 1999; 28: 800-807. Go to original source... Go to PubMed...
    8. Kox JW, Bone RC, Krausch D, et al. Interferon gamma-1b in the treatment of compensatory anti-inflammatory response syndrom. Arch Intern Med 1997; 157: 389-394. Go to original source...
    9. Nakamura T, Matsuda T, Suzuki Y, et al. Polymyxin B-immobilized fiber hemoperfusion in patients with sepsis. Dialysis and Transplantation 2003; 10: 602-607.
    10. Nasraway SA. The problems and challenges of immunotherapy in sepsis. Chest 2003, 5: 451-459. Go to original source... Go to PubMed...
    11. Ono S, Tsujimoto H, Matsumoti A, et al. Modulation of human leukocyte antigen on monocytes and cd16 on granulocytes in patients with septic shock using hemoperfusion with polymyxin b-immobilized fiber. American Journal of Surgery 2004; 8. Go to original source... Go to PubMed...
    12. Presneill JJ, Harris T, Stewart AG, et al. A randomized phase II trials granulocyte-macrophage colony-stimulating factor therapy in severe sepsis with respiratory dysfunction. Am J Respir Crit Care Med 2002; 166: 138-143. Go to original source... Go to PubMed...
    13. Reinhart K, Hellman MA, Beale R, et al. Open randomised phase II trial of an extracorporeal endotoxin adsorber in suspected Gram-negative sepsis. Crit Care Med 2004; 8: 1662-1668. Go to original source... Go to PubMed...
    14. Shoji H. Extracorporeal endotoxin removal for the treatment os sepsis: endotoxin adsorption cartridge. Therapeutic Apheresis and Dialysis 2003; 7: 108-114. Go to original source... Go to PubMed...
    15. Uriu K, Osajima A, Hiroshige K, et al. Endotoxin removal by direct hemoperfusion with an adsorbent column using polymyxin B-immobilized fiber ameliorates systemic circulatory disturbance in patients with septic shock. American Journal of Kidney Diseases 2002; 5. Go to original source... Go to PubMed...
    16. Werdan K. Immunoglobulins in sepsis: therapeutic use of immunoglobulins. Sepsis 1999; 3: 239-245. Go to original source...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.